Canaccord starts Mast Therapeutics (MSTX +15%) at Buy.
Analyst Ritu Baral likes MST-188's (Orphan designation in Europe) chances in sickle cell, and says EPIC "is well designed enough to to support FDA and EMA approval by itself if ... successful." Expect read-out in 2016.
Baral sees U.S. market launch in 2017 and peak sales of around $400M by 2023.
Price target is $3, which, even counting this morning's double-digit gains, translates into a 477% upside.